InflaRx N.V.
Close on Oct 19, 2026
About InflaRx
Pharmaceutical Preparations, SIC 2834
InflaRx N.V. is a biopharmaceutical company that discovers and develops treatments for complement-mediated inflammatory and immunological diseases. The company utilizes proprietary anti-C5a and anti-C5aR technologies to target debilitating conditions. Its primary product is vilobelimab, marketed as GOHIBIC, which holds emergency use authorization in the United States and marketing authorization in Europe for treating severe COVID-19. InflaRx also develops vilobelimab for additional inflammatory indications, alongside pipeline candidates including izicopan and IFX002. These therapies target patients suffering from severe immune disorders and the healthcare systems that treat them.
The company is incorporated under Dutch law and maintains its principal executive offices and headquarters in Jena, Germany. InflaRx operates with a compact workforce, and substantially all of its assets are situated outside the United States. Furthermore, the majority of its directors and executive officers live outside the United States. Its clinical and commercial supply relationships with contract manufacturers span Europe and the United States.
Summary of the business section of InflaRx's latest annual report, written by StockData.
Company profile
Company
- Legal name
- InflaRx N.V.
- Headquarters
- Jena, 2M
- Address
- Winzerlaer Str. 2 07745
- Phone
- 49 3641 508180
- Industry
- Pharmaceutical Preparations
- Incorporated in
- P7
- Fiscal year ends
- December 31
- Auditor
- KPMG AG Wirtschaftsprufungsgesellschaft, Munich, Germany
Stock & identifiers
- Ticker
- IFRX
- Exchange
- Nasdaq
- IPO date
- Nov 8, 2017
- Shares outstanding
- 72M, Dec 31, 2025
- Filer category
- Non-accelerated filer
- SEC CIK
- 1708688
- CUSIP
- N44821101
- ISIN
- USN448211011
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Renfeng Guo | Chief Scientific Officer, Director | 1,762,144 |
| Niels Riedemann | Chief Executive Officer, Director | 1,068,908 |
| Thomas Taapken | Chief Financial Officer | 3,500 |
| Derval OCarroll | See Remarks | – |
| Mark Kubler | Director | 960,015 |
| Nicolas Fulpius | Director | 490,052 |
| Hege Hellstrom | Director | – |
| Anthony S. Gibney | Director | 10,000 |
| Richard Brudnick | Director | 50,000 |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Nov 8, 2017 | IPO | Initial public offering priced (424B4 prospectus) |
| Nov 8, 2017 | Name change | Name changed from Fireman B.V. to InflaRx N.V. |
| Nov 7, 2017 | Listing | Registration of securities on an exchange (Form 8-A) |